We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0QAV market cap is 300.83M. The company's latest EPS is EUR -0.8423 and P/E is -3.36.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Revenue | 2.54M | 2.51M | 2.65M | 4.78M | 36.21M |
| Operating Income | -46.67M | -36.39M | -52.51M | -46.47M | -26.62M |
| Net Income | -50.92M | -33.59M | -47M | -57.04M | -39.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Total Assets | 56.21M | 134.03M | 101.77M | 59.77M | 93.9M |
| Total Liabilities | 58.11M | 63.56M | 74.98M | 86.81M | 95.74M |
| Total Equity | -1.91M | 70.47M | 26.79M | -27.05M | -1.84M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| EUR (€) | EUR (€) | EUR (€) | EUR (€) | EUR (€) | |
| Operating | -41.17M | -27.54M | -29.87M | -37.1M | -12.48M |
| Investing | -1.46M | -111k | -242k | 137k | -349k |
| Financing | 41.49M | 111.77M | -5.18M | -5.65M | 46.77M |
| Market Cap | 300.83M |
| Price to Earnings Ratio | -3.36 |
| Price to Sales Ratio | 3.68 |
| Price to Cash Ratio | 1.77 |
| Price to Book Ratio | -72.37 |
| Dividend Yield | - |
| Shares Outstanding | 47.13M |
| Average Volume (1 week) | 6.63k |
| Average Volume (1 Month) | 3.09k |
| 52 Week Change | 0.00% |
| 52 Week High | 6.3825 |
| 52 Week Low | 6.3825 |
| Spread (Intraday) | 0.32 (4.82%) |
| Company Name | Nanobiotix Sa |
| Address |
60 rue de wattignies paris, paris 75012 |
| Website | https://www.nanobiotix.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
